Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01459796 · ClinicalTrials.gov registry record · Phase 3
Study of the Safety and Efficacy of Long-Term Rilonacept Treatment for the Prevention of Gout Flares
A Phase 3 study, sponsored by Regeneron Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 220
- Enrollment target
NCT01459796 is a Phase 3 study that was terminated before completion, run by Regeneron Pharmaceuticals. The registered enrollment target is 220 participants.
The verdict
NCT01459796, a Phase 3 study, was terminated before completion, sponsored by Regeneron Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 220 participants
- Enrollment target
Study Summary
The purpose of this study was to determine the safety and tolerability of rilonacept for participants with gout who were initiating allopurinol.
Interventions
- DRUG Placebo
- DRUG Allopurinol
- DRUG Rilonacept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2011-11 |
| Est. Completion | 2013-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01459796
The ClinicalTrials.gov registry entry for NCT01459796 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 220 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01459796 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01459796 about?
NCT01459796 is a clinical study titled "Study of the Safety and Efficacy of Long-Term Rilonacept Treatment for the Prevention of Gout Flares". The purpose of this study was to determine the safety and tolerability of rilonacept for participants with gout who were initiating allopurinol.
What is the current status of trial NCT01459796?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 220 participants. The study started on 2011-11. Estimated completion is 2013-06.
What interventions are being tested in trial NCT01459796?
The interventions under investigation include: Placebo (DRUG), Allopurinol (DRUG), Rilonacept (DRUG).
Who is sponsoring clinical trial NCT01459796?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.